Chemical Engineering @ChemengFiles.Com

Any process that must be monitored requires sensors to find the variables of a process in real time. If required to monitor a large number of variables in the process, in the same proportion will require a large number of sensors for these variables. The sensors are costly, require maintenance, and can be calibrated become very sensitive, besides needing a hardware that connects with the monitoring unit. Would not it be better if we could dispense with a few sensors and still be able to monitor the whole process?

Any process that must be monitored requires sensors to find the variables of a process in real time. If required to monitor a large number of variables in the process, in the same proportion will require a large number of sensors for these variables. The sensors are costly, require maintenance, and can be calibrated become very sensitive, besides needing a hardware that connects with the monitoring unit. Would not it be better if we could dispense with a few sensors and still be able to monitor the whole process?

Individual will be responsible for providing functional and IPT planning as required, including: planning and scheduling support, performance assessment and analysis, visibility, metrics development and presentations. Tasks include all aspects of EVMS reporting and application including use of tailored tool to provide the necessary visibility charts; EAC development, development of performance metrics, charts and ad hoc reports, and ability to communicate and summarize detailed data to management/IPTs.

Individual will be responsible for providing functional and IPT planning as required, including: planning and scheduling support, performance assessment and analysis, visibility, metrics development and presentations. Tasks include all aspects of EVMS reporting and application including use of tailored tool to provide the necessary visibility charts; EAC development, development of performance metrics, charts and ad hoc reports, and ability to communicate and summarize detailed data to management/IPTs.

ERYtech Pharma has been chosen to present the initial results obtained with its preclinical product GR-ARA1 on sickle cell anemia at the 50th annual congress of the American Society of Hematology (ASH), to be held in San Francisco (United States) from 6 to Dec. 9, 2008.

Sickle cell disease is a genetic disease characterized by the presence of sickle red blood cells in patients suffering from hypoxia (about 100,000 cases in Europe and North America).

ERYtech Pharma has been chosen to present the initial results obtained with its preclinical product GR-ARA1 on sickle cell anemia at the 50th annual congress of the American Society of Hematology (ASH), to be held in San Francisco (United States) from 6 to Dec. 9, 2008.

Sickle cell disease is a genetic disease characterized by the presence of sickle red blood cells in patients suffering from hypoxia (about 100,000 cases in Europe and North America).